Natco Fights Back After Charges Of Marketing Substandard Albupax Drug; Says Test Kits Yielding Varying Results
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Controversy over the charges leveled by India's drug controller on Natco Pharma for allegedly selling substandard anti-cancer drug Albupax thickened as the Hyderabad-headquartered company openly blamed competition for "resorting to an insidious campaign through selective leaks and half-truths to malign its image and reputation.